Statins in prevention of repeat revascularization after percutaneous coronary intervention-A meta-analysis of randomized clinical trials

Pharmacological Research

Volumn 61, Issue 4, 2010, Pages 316-320

  Zhang, Zhi Jiang ^a   Cheng, Qi ^a   Jiang, Guo Xin ^a,b   Marroquin, Oscar C ^c,d  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Mortality; Percutaneous coronary intervention; Repeat revascularization; Statin

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFICACY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REOPERATION; RISK REDUCTION; SYSTEMATIC REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, BALLOON; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT;

EID: 77649342307     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.11.004     Document Type: Article

References (28)

1. Zhang Z.J., Marroquin O.C., Weissfeld J.L., Stone R.A., Mulukutla S.R., Williams D.O., et al. Beneficial effects of statins after percutaneous coronary intervention. Eur J Cardiovasc Prev Rehabil 16 4 (2009) 445-450
2. Kasai T., Miyauchi K., Kurata T., Satoh H., Ohta H., Tanimoto K., et al. Long-term (11-year) statin therapy following percutaneous coronary intervention improves clinical outcome and is not associated with increased malignancy. Int J Cardiol 114 2 (2007) 210-217
3. Bertrand M.E., McFadden E.P., Fruchart J.C., Van Belle E., Commeau P., Grollier G., et al. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of restenosis by elisor after transluminal coronary angioplasty. J Am Coll Cardiol 30 4 (1997) 863-869
4. Mulder H.J., Bal E.T., Jukema J.W., Zwinderman A.H., Schalij M.J., van Boven A.J., et al. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial). Am J Cardiol 86 7 (2000) 742-746
5. Schartl M., Bocksch W., Koschyk D.H., Voelker W., Karsch K.R., Kreuzer J., et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 104 4 (2001) 387-392
6. Serruys P.W., de Feyter P., Macaya C., Kokott N., Puel J., Vrolix M., et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287 24 (2002) 3215-3222
7. Okazaki S., Yokoyama T., Miyauchi K., Shimada K., Kurata T., Sato H., et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation 110 9 (2004) 1061-1068
8. Bae J.H., Bassenge E., Kim K.Y., Synn Y.C., Park K.R., and Schwemmer M. Effects of low-dose atorvastatin on vascular responses in patients undergoing percutaneous coronary intervention with stenting. J Cardiovasc Pharmacol Ther 9 3 (2004) 185-192
9. Ebrahimi R., Saleh J., Toggart E., Shah A.P., Azmoon S., Babaei H., et al. Effect of preprocedural statin use on procedural myocardial infarction and major cardiac adverse events in percutaneous coronary intervention: a meta-analysis. J Invasive Cardiol 20 6 (2008) 292-295
10. Mood G.R., Bavry A.A., Roukoz H., and Bhatt D.L. Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention. Am J Cardiol 100 6 (2007) 919-923
11. Geisler T., Zurn C., Paterok M., Gohring-Frischholz K., Bigalke B., Stellos K., et al. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. Eur Heart J 29 13 (2008) 1635-1643
12. Mulukutla S.R., Marroquin O.C., Smith C., Varghese R., Anderson W.D., Lee J.S., et al. Effect of statin therapy prior to elective percutaneous coronary intervention on frequency of periprocedural myocardial injury. Am J Cardiol 94 11 (2004) 1363-1366
13. Hong Y.J., Jeong M.H., Hyun D.W., Hur S.H., Kim K.B., Kim W., et al. Prognostic significance of simvastatin therapy in patients with ischemic heart failure who underwent percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 95 5 (2005) 619-622
14. Serruys P.W., Foley D.P., Jackson G., Bonnier H., Macaya C., Vrolix M., et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 20 1 (1999) 58-69
15. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 3 (1986) 177-188
16. Begg C.B., and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50 4 (1994) 1088-1101
17. Kip K.E., Hollabaugh K., Marroquin O.C., and Williams D.O. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. J Am Coll Cardiol 51 7 (2008) 701-707
18. Yamawaki T., Yamada A., Fukumoto Y., Kishi T., Sobashima A., Kuwata K., et al. Statin therapy may prevent restenosis after successful coronary intervention, independent of lipid-lowering effect and CRP level. Fukuoka Igaku Zasshi 98 6 (2007) 260-269
19. Johnson C., Waters D.D., DeMicco D.A., Breazna A., Bittner V., Greten H., et al. Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study). Am J Cardiol 102 10 (2008) 1312-1317
20. Chan K.C., Wang C.J., Ho H.H., Chen H.M., and Huang C.N. Simvastatin inhibits cell cycle progression in glucose-stimulated proliferation of aortic vascular smooth muscle cells by up-regulating cyclin dependent kinase inhibitors and p53. Pharmacol Res 58 3-4 (2008) 247-256
21. Weintraub W.S., Boccuzzi S.J., Klein J.L., Kosinski A.S., King III S.B., Ivanhoe R., et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. N Engl J Med 331 20 (1994) 1331-1337
22. Nasu K., Tsuchikane E., Katoh O., Tanaka N., Kimura M., Ehara M., et al. Effect of fluvastatin on progression of coronary atherosclerotic plaque evaluated by virtual histology intravascular ultrasound. JACC Cardiovasc Interv 2 7 (2009) 689-696
23. Yonemura A., Momiyama Y., Fayad Z.A., Ayaori M., Ohmori R., Kihara T., et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques: a 2-year follow-up by noninvasive MRI. Eur J Cardiovasc Prev Rehabil 16 2 (2009) 222-228
24. Aydin S., Uzun H., Sozer V., and Altug T. Effects of atorvastatin therapy on protein oxidation and oxidative DNA damage in hypercholesterolemic rabbits. Pharmacol Res 59 4 (2009) 242-247
25. Thygesen K., Alpert J.S., and White H.D. Universal definition of myocardial infarction. Eur Heart J 28 20 (2007) 2525-2538
26. Briguori C., Visconti G., Focaccio A., Golia B., Chieffo A., Castelli A., et al. Novel approaches for preventing or limiting events (naples) II trial impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol (2009)
27. Patti G., Pasceri V., Colonna G., Miglionico M., Fischetti D., Sardella G., et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 49 12 (2007) 1272-1278
28. Blagojevic A., Delaney J.A., Levesque L.E., Dendukuri N., Boivin J.F., and Brophy J.M. Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: a cohort study. Pharmacoepidemiol Drug Saf 18 5 (2009) 362-369